

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/086,745	02/28/2002	Gary de Jong	24601-416C	8781
24961	7590 10/02/2003	EXAMINER		INER
	EHRMAN WHITE & M	LAMBERTSON, DAVID A		
	LLA VILLAGE DRIVE			
7TH FLOOI	R		ART UNIT	PAPER NUMBER
SAN DIEGO	SAN DIEGO, CA 92122-1246			15
			DATE MAILED: 10/02/2002	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Amplicant (a)				
	Application No.	Applicant(s)				
Office Action Summan	10/086,745	DE JONG ET AL.				
Office Action Summary	Examin r	Art Unit				
The MANUAL DATE of this communication and	David A. Lambertson	1636				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status						
1) Responsive to communication(s) filed on 28 C	<u> October 2002</u> .					
2a)☐ This action is FINAL . 2b)⊠ Thi	s action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims 4)						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6) Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) 1-32 are subject to restriction and/or election requirement.						
Application Papers						
9)☐ The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11)☐ The proposed drawing correction filed on is: a)☐ approved b)☐ disapproved by the Examiner.						
If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) ☐ All b) ☐ Some * c) ☐ None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachment(s)						
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal F	v (PTO-413) Paper No(s) Patent Application (PTO-152)				

Application/Control Number: 10/086,745

Art Unit: 1636

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-16 and 30, drawn to a method of detecting the delivery and expression of a nucleic acid into a cell by measuring the activity of a reporter gene expression product, classified in class 435, subclass 4.
- II. Claims 17-22 and 31, drawn to a method of monitoring the delivery of a nucleic acid into a cell by measuring a labeled nucleic acid, classified in class 435, subclass 6.
- III. Claims 23-29 and 32, drawn to a method of screening an agent with the ability to deliver a nucleic acid into a cell by measuring the number of cells containing a label, classified in class 435, subclass 440.

The inventions are distinct, each from the other because of the following reasons:

Inventions I and II are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions have different modes of operation and different effects, and are not disclosed as capable of being used together. Specifically, invention I is directed to an outcome where the activity of a reporter gene (i.e., a protein activity) is measured, whereas invention II is directed to an outcome where a nucleic acid is measured. The inventions require different method steps leading to different outcomes (measuring a protein activity versus detecting the presence of a

Application/Control Number: 10/086,745

Art Unit: 1636

nucleic acid), thus the inventions have different modes of operation and effects, and are patentably distinct.

Inventions I-II and III are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions have different effects and modes of operation, and are not disclosed as capable of being used together. Specifically, inventions I and II are directed to methods of detecting the delivery of a nucleic acid, which is a different outcome from that of invention III which is directed to a method of identifying agents with the ability to deliver nucleic acids to cells. The outcomes are different because I and II measure the delivery of a nucleic acid, whereas invention III identifies an agent that delivers a nucleic acid, thus the inventions have different effects. Furthermore, invention III requires a method step (the contacting of cells/nucleic acids with different "agents") that is not present in either invention I or II, thus the inventions also have different modes of operation. Because the inventions have different effects and modes of operation, the inventions are patentably distinct.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper. Furthermore, especially in instances where the classifications are the same, the non-patent literature searches required for each of these inventions are not coextensive, hence said searches would be burdensome. Therefore restriction for examination purposes as indicated is proper.

Page 4

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David A. Lambertson whose telephone number is (703) 308-8365. The examiner can normally be reached on 6:30am to 4pm, Mon.-Fri., first Friday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Remy Yucel, Ph.D. can be reached on (703) 305-1998. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

PRIMARY EXAMINER

David A. Lambertson

AU 1636